JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 50(2016) N 6 p. 880-886; DOI 10.1134/S0026893316050022 Full Text

O.Y. Agapova1, Y.S. Skoblov2*, G.A. Tkachev3, N.A. Mironova3, S.P. Golitsyn3, V.P. Masenko3, I.E. Chazova3, K.A. Zykov1

Changes in the receptor activity of β2-adrenoreceptors of human T-lymphocytes under the effect of β2-agonists

1Moscow State University of Medicine and Dentistry, Laboratory of Pulmonology, Moscow, 127473 Russia
2Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia
3Russian Cardiology Research and Production Complex, Moscow, 121552 Russia

*sur@ibch.ru
Received - 2015-10-21; Accepted - 2015-12-17

Changes in the activity of β2-adrenergic receptors of human T-lymphocytes under the effect of salbutamol (a short-acting β2-agonist) have been evaluated with a new modified radioligand method utilizing [125I]cyanopindolol and a specific ligand ICI 118551. In healthy volunteers, the receptor activity decreased after 30 min upon the inhalation of salbutamol and restored to the initial level after 2 h. At the same time, there were changes in the transcription level of the ADRB2 gene, which encodes the protein component of the β2-adrenoreceptor. The dynamics of β2-adrenergic receptor activity of T-lymphocytes after salbutamol treatment in patients with cardiorespiratory pathology significantly differed from that in healthy volunteers.

radioligand binding assay, activity of β2-adrenoreceptors, ADRB2, gene expression, T-lymphocytes



JMB-FOOTER RAS-JOURNALS